Search: id:"swepub:oai:lup.lub.lu.se:01fe584c-bca0-41c6-b9ea-a5dd9e59239f" >
Measuring factor IX...
-
Bowyer, A. E.Sheffield Teaching Hospitals
(author)
Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits : A two-center study
- Article/chapterEnglish2016
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:01fe584c-bca0-41c6-b9ea-a5dd9e59239f
-
https://lup.lub.lu.se/record/01fe584c-bca0-41c6-b9ea-a5dd9e59239fURI
-
https://doi.org/10.1111/jth.13348DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Essentials: Validated assays are required to precisely measure factor IX (FIX) activity in FIX products. N9-GP and two other FIX products were assessed in various coagulation assay systems at two sites. Large variations in FIX activity measurements were observed for N9-GP using some assays. One-stage and chromogenic assays accurately measuring FIX activity for N9-GP were identified. Summary: Background: Measurement of factor IX activity (FIX:C) with activated partial thromboplastin time-based one-stage clotting assays is associated with a large degree of interlaboratory variation in samples containing glycoPEGylated recombinant FIX (rFIX), i.e. nonacog beta pegol (N9-GP). Validation and qualification of specific assays and conditions are necessary for the accurate assessment of FIX:C in samples containing N9-GP. Objectives: To assess the accuracy of various one-stage clotting and chromogenic assays for measuring FIX:C in samples containing N9-GP as compared with samples containing rFIX or plasma-derived FIX (pdFIX) across two laboratory sites. Methods: FIX:C, in severe hemophilia B plasma spiked with a range of concentrations (from very low, i.e. 0.03 IU mL-1, to high, i.e. 0.90 IU mL-1) of N9-GP, rFIX (BeneFIX), and pdFIX (Mononine), was determined at two laboratory sites with 10 commercially available one-stage clotting assays and two chromogenic FIX:C assays. Assays were performed with a plasma calibrator and different analyzers. Results: A high degree of variation in FIX:C measurement was observed for one-stage clotting assays for N9-GP as compared with rFIX or pdFIX. Acceptable N9-GP recovery was observed in the low-concentration to high-concentration samples tested with one-stage clotting assays using SynthAFax or DG Synth, or with chromogenic FIX:C assays. Similar patterns of FIX:C measurement were observed at both laboratory sites, with minor differences probably being attributable to the use of different analyzers. Conclusions: These results suggest that, of the reagents tested, FIX:C in N9-GP-containing plasma samples can be most accurately measured with one-stage clotting assays using SynthAFax or DG Synth, or with chromogenic FIX:C assays.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Hillarp, A.Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,Skåne University Hospital(Swepub:lu)klke-ahi
(author)
-
Ezban, M.Novo Nordisk A/S
(author)
-
Persson, P.Novo Nordisk A/S(Swepub:lu)tde-ppe
(author)
-
Kitchen, S.Sheffield Teaching Hospitals
(author)
-
Sheffield Teaching HospitalsKlinisk kemi, Malmö
(creator_code:org_t)
Related titles
-
In:Journal of Thrombosis and Haemostasis: Elsevier BV14:7, s. 1428-14351538-79331538-7836
Internet link
Find in a library
To the university's database